CN104168910B - 肽及其用途 - Google Patents

肽及其用途 Download PDF

Info

Publication number
CN104168910B
CN104168910B CN201380013630.6A CN201380013630A CN104168910B CN 104168910 B CN104168910 B CN 104168910B CN 201380013630 A CN201380013630 A CN 201380013630A CN 104168910 B CN104168910 B CN 104168910B
Authority
CN
China
Prior art keywords
cells
cell
peptide
adiponectin
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380013630.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104168910A (zh
Inventor
乔治·爱德华·雷格尔
帕尔特·纳伦德兰
海伦·麦格特里克
马里亚姆·希梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Birmingham
Original Assignee
University of Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Birmingham filed Critical University of Birmingham
Publication of CN104168910A publication Critical patent/CN104168910A/zh
Application granted granted Critical
Publication of CN104168910B publication Critical patent/CN104168910B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
CN201380013630.6A 2012-01-13 2013-01-14 肽及其用途 Active CN104168910B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1200555.9 2012-01-13
GB201200555A GB201200555D0 (en) 2012-01-13 2012-01-13 Peptide
PCT/GB2013/050068 WO2013104928A1 (en) 2012-01-13 2013-01-14 Peptide and uses thereof

Publications (2)

Publication Number Publication Date
CN104168910A CN104168910A (zh) 2014-11-26
CN104168910B true CN104168910B (zh) 2017-07-28

Family

ID=45813974

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380013630.6A Active CN104168910B (zh) 2012-01-13 2013-01-14 肽及其用途

Country Status (7)

Country Link
US (1) US9597368B2 (https=)
EP (1) EP2802342B1 (https=)
JP (1) JP6055845B2 (https=)
CN (1) CN104168910B (https=)
GB (1) GB201200555D0 (https=)
IN (1) IN2014DN05784A (https=)
WO (1) WO2013104928A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165218A1 (en) * 2017-03-09 2018-09-13 Allysta Pharmaceuticals, Inc Peptides for dry eye disease
US12226449B2 (en) * 2018-11-15 2025-02-18 The University Of Toledo Materials and methods for the prevention of rheumatoid arthritis
US20210100870A1 (en) * 2019-10-08 2021-04-08 The University Of Birmingham Bone disease treatment
GB202211043D0 (en) 2022-07-28 2022-09-14 Univ Birmingham Peptide agonist
CN117244043B (zh) * 2023-11-02 2024-09-20 徐州医科大学附属医院 破伤风类毒素在治疗血管内皮细胞损伤中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101925364A (zh) * 2007-11-27 2010-12-22 不列颠哥伦比亚大学 用于预防和治疗关节炎的14-3-3拮抗剂
US20110130415A1 (en) * 2009-12-01 2011-06-02 Rajinder Singh Protein kinase c inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002216273A1 (en) 2000-12-29 2002-07-16 Oxford Glycosciences (Uk) Limited Proteins, genes and their use for diagnosis and treatment of kidney response
EP2132183B1 (en) * 2007-02-28 2015-06-03 University Of Virginia Patent Foundation Lisofylline analogs and methods for use
WO2010040029A1 (en) * 2008-10-02 2010-04-08 Celtaxsys, Inc. Methods of modulating the negative chemotaxis of immune cells
WO2011154496A1 (en) 2010-06-09 2011-12-15 Poxel Treatment of type 1 diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101925364A (zh) * 2007-11-27 2010-12-22 不列颠哥伦比亚大学 用于预防和治疗关节炎的14-3-3拮抗剂
US20110130415A1 (en) * 2009-12-01 2011-06-02 Rajinder Singh Protein kinase c inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bile Proteomic Profiles Differentiate Cholangiocarcinoma from Primary Sclerosing Cholangitis and Choledocholithiasis;LANKISCH ET AL.;《HEPATOLOGY》;20110103;第53卷(第3期);第875-884页 *

Also Published As

Publication number Publication date
JP6055845B2 (ja) 2016-12-27
WO2013104928A1 (en) 2013-07-18
US9597368B2 (en) 2017-03-21
GB201200555D0 (en) 2012-02-29
IN2014DN05784A (https=) 2015-05-15
US20150051137A1 (en) 2015-02-19
EP2802342B1 (en) 2018-05-02
CN104168910A (zh) 2014-11-26
JP2015509095A (ja) 2015-03-26
EP2802342A1 (en) 2014-11-19

Similar Documents

Publication Publication Date Title
Herold et al. The immunology of type 1 diabetes
CN112972492B (zh) Nk细胞中对细胞因子诱导的sh2蛋白的抑制
KR101862291B1 (ko) 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정을 예방하거나 치료하기 위한 조성물 및 방법
CN104168910B (zh) 肽及其用途
US20110020269A1 (en) Methods and compositions for modifying t cell immune responses and inflammation
CN103732241A (zh) 低剂量il-2用于治疗自身免疫相关病症或炎性病症的应用
EP3149049B1 (en) Il-22 for use in treating metabolic disorders
JP2012501973A (ja) 痛みの治療に関する薬剤及び方法
KR102442984B1 (ko) 글루카곤 수용체 길항 항체를 이용한 제 1 형 당뇨병의 치료 방법
US20110059949A1 (en) Prophylaxis and treatment of infectious diseases
CA2944811A1 (en) Combination therapy for the treatment of autoimmune diseases
Ren et al. Inhibitor of differentiation-2 protein ameliorates DSS-induced ulcerative colitis by inhibiting NF-κB activation in neutrophils
KR20160124236A (ko) 만성 폐 동종이식편 기능이상 및 특발성 폐 섬유증의 예방 또는 치료를 위한 조성물 및 방법
Deng et al. Interleukin-17 family in health and immune diseases: From origin to clinical implications
KR20170044171A (ko) 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정의 예방 또는 치료용 조성물 및 방법
US9839671B2 (en) Peptide and uses therefor
US20230181563A1 (en) Akt3 modulators and methods of use thereof
Rodríguez et al. Type I interferons regulate nitric oxide production in Brucella abortus-activated microglia contributing to neuronal death
JP2019520341A (ja) 代謝疾患を治療する組成物と方法
JP2022524585A (ja) 新規ペプチドおよびその用途
WO2014182601A1 (en) A method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the atp/p2x7r axis)
TWI598101B (zh) 用於心臟再生的治療性基因混合製劑
Coronel et al. Yixiang Zhan1, Yingbo Wang2, Boya Zhang1, Yijun Zhang2, Rui Liang1, Jiuxia Yang1, Tengli Liu1, Xiaoyan Hu1, Tianyi You1, Na Liu1, Yuqi Chen2, Qing Liu2, Tingsheng Jiang2, Zhaoce Liu1, Xiangheng Cai1, Runnan Yang2, Yingyi Qi2, Peng Sun1, Jiaqi Zou1, Xuejie Ding1, Zhuzeng Yin3 and Shusen Wang1
Butcher et al. Targeting Acid-Sensing Ion Channels
Zhan et al. Xuebijing injection mitigates instant blood− mediated inflammatory reaction and enhances intrahepatic islet transplantation via target NF− κB pathway

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant